Isavuconazole: Phase III resumed

Basilea said in its 2010 earnings that it and partner Astellas resumed a double-blind, international Phase III trial comparing isavuconazole vs. caspofungin followed by voriconazole in 526 patients. In August 2009, Basilea suspended enrollment in the study, which had already enrolled about 40% of the planned patients, due to a clinical supply delay, and was further delayed in September 2010 to allow the use of the compound manufactured at the commercial-scale production line (see BioCentury, Sept. 20, 2010). ...